Figure 1From: Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers Progression-free (PFS) and overall survival (OS) of metastatic RCC patients treated with sunitinib. Dotted lines represent confidence intervals. Median PFS = 268 days (8.9 months, 95% CI: 195 to 342 days) and median OS = 487 days (16.2 months, 95% CI, 236 to 738 days).Back to article page